Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Recombinetics
- Ownership
- Private
- Development stage
- Other
01
Overview
Recombinetics operates primarily in preclinical development with swine reporter models for gene therapy and gene editing validation, as well as cancer models for preclinical testing. The company has developed multiple disease models and launched commercial swine reporter models in 2024.
- Therapeutic areas
- NephrologyCardiovascularNeurologyRare DiseasesOncology
- Modalities
- Gene therapyCell therapyGene editing
- Industry
- Non-Drug Biotech
Beyond the preview
Go deeper on Recombinetics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recombinetics.